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FUNCTIONAL ELECTRICAL STIMULATION AND ANKLE FOOT ORTHOSES PROVIDE 
EQUIVALENT THERAPEUTIC EFFECTS ON FOOT DROP: A META-ANALYSIS 
PROVIDING DIRECTION FOR FUTURE RESEARCH
Sarah PRENTON, BSc1, Kristen L. HOLLANDS, PhD2, Laurence P. J. KENNEY, PhD2 and Pornsuree ONMANEE, PhD2
From the 1University of Huddersfield, School of Human and Health Sciences, Department of Health Sciences, Health and Rehabilitation 
Division and 2University of Salford, School of Health Sciences, Salford, UK
Objective: To compare the randomized controlled 
trial evidence for therapeutic effects on walking of 
functional electrical stimulation and ankle foot ort-
hoses for foot drop caused by central nervous sys-
tem conditions.
Data sources: MEDLINE, CINAHL, Cochrane Central 
Register of Controlled Trials, REHABDATA, PEDro, 
NIHR Centre for Reviews and Dissemination, Scopus 
and clinicaltrials.gov.
Study selection: One reviewer screened titles/abst-
racts. Two independent reviewers then screened the 
full articles.
Data extraction: One reviewer extracted data, an-
other screened for accuracy. Risk of bias was asses-
sed by 2 independent reviewers using the Cochrane 
Risk of Bias Tool.
Data synthesis: Eight papers were eligible; 7 invol-
ving participants with stroke and 1 involving partici-
pants with cerebral palsy. Two papes reporting dif-
ferent measures from the same trial were grouped, 
resulting in 7 synthesized randomized controlled 
trials (n= 464). Meta-analysis of walking speed at 
final assessment (p = 0.46), for stroke participants 
(p = 0.54) and after 4–6 weeks’ use (p = 0.49) sho-
wed equal improvement for both devices.
Conclusion: Functional electrical stimulation and 
ankle foot orthoses have an equally positive thera-
peutic effect on walking speed in non-progressive 
central nervous system diagnoses. The current ran-
domized controlled trial evidence base does not 
show whether this improvement translates into the 
user’s own environment or reveal the mechanisms 
that achieve that change. Future studies should fo-
cus on measuring activity, muscle activity and gait 
kinematics. They should also report specific device 
details, capture sustained therapeutic effects and in-
volve a variety of central nervous system diagnoses. 
Key words: electric stimulation therapy; foot orthoses; 
walking; foot drop; central nervous system; therapeutic ef-
fects; systematic review; meta-analysis.
Accepted Sep 29, 2017; Epub ahead of print xx, 2017
J Rehabil Med 2017; 00: 00–00
Correspondence address: Sarah Prenton, Room RG/23, Ramsden Buil-
ding University of Huddersfield, Queensgate, Huddersfield, West York-
shire, HD1 3DH Huddersfield, UK. E-mail: s.prenton@hud.ac.uk
Foot drop is a common motor impairment associated with many central nervous system (CNS) condi-
tions (1). An estimated 20–30% of stroke survivors 
experience foot drop; thus approximately 240,000–
360,000 people might be living with it in the UK 
alone (2). Foot drop is an abnormal activation of the 
musculature of the lower limb, resulting in inefficient 
foot clearance during swing (3) and reduced stability 
in stance (4). These impairments negatively impact the 
function of walking, which may restrict participation 
in many aspects of life. 
There are 2 demonstrably effective orthotic interven-
tions for foot drop: ankle-foot orthoses (AFO) (5–9) 
and functional electrical stimulation (FES) devices 
(10). AFOs address foot drop by changing the effective 
stiffness and neutral point of the ankle joint (11). FES 
devices stimulate lower motor neurones, in this case the 
common peroneal nerve, to assist muscle contraction 
over appropriate phases in the gait cycle (12).
Recent randomized controlled trials (RCT) have 
sought to compare the direct effects of using each 
device on various walking behaviours (13, 14). These 
comparisons have been made both with and without 
the devices being worn, at the point of provision and at 
various time-points after a period of use (15). Clinically 
the devices are commonly prescribed as orthotics for 
long-term use (16); the difference between walking 
behaviours without the device at baseline and walking 
with the device being worn after a period of use is 
called the combined-orthotic effects (14). RCTs (14, 
17–19) reporting these effects have found that both 
devices achieve the same improvement at various 
time-points up 12 months (18). The combined results 
of individual RCTs, demonstrating equal combined-
orthotic effects of AFO and FES, have also been 
confirmed in a recent meta-analysis (15). However, 
given the clinical importance of attempting to achieve 
therapeutic benefits (20, 21) (i.e. improvement in mea-
sured walking behaviours without a device being worn 
relative to baseline, called the therapeutic effects (13)), 
further work is required to establish whether there are 
differences in the therapeutic effects of the 2 devices. 
The first study of FES reported that some users, fol-
lowing a period of use, experienced improvement even 
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2 S. Prenton et al.
after the device was removed (22). More recently, a 
number of studies have suggested a range of possible 
peripheral and central neural mechanisms to explain 
these observations (23–26). In contrast, an AFO is a 
purely mechanical device and there appears to be an 
assumption that the effects of AFO on walking are seen 
only when the device is worn (27). In addition, some 
studies suggest that AFO use may lead to muscle weak-
ening (4, 28–31), whereas FES has been suggested to 
improve volitional muscle activation (25).
These studies appear to predict differential therapeu-
tic effects between the 2 devices, which makes the find-
ings (18) of an equivalent combined-orthotic effect of 
the devices somewhat surprising; as one might expect 
improvements in therapeutic effects to be positively 
correlated with combined-orthotic effects. Therefore a 
review of therapeutic effects is needed to help inform 
guidelines for clinical use.
While a number of AFO- and FES-specific reviews 
have been published, only 2 of these have attempted 
to draw direct comparisons (16, 32). RCT-based direct 
comparisons are particularly important as they summa-
rize current thinking about mechanisms-of-effect and 
how these impact on function. This information can 
then be used to advance clinical guidelines, which is 
timely in the face of increasing market choice for both 
devices. However, neither of the existing reviews (16, 
32) could be considered a gold standard meta-analysis, 
due to methodological issues, and hence there remains 
a need to pool RCT-level evidence to answer the fol-
lowing specific questions:
1. Are the therapeutic effects on the function of walking 
for CNS foot drop different for FES and AFO? 
i) Does diagnosis impact these therapeutic effects? 
ii) Does time of use impact these therapeutic effects?
2. What are the mechanisms of therapeutic effects of 
AFO and FES on walking for CNS foot drop? 
By answering these questions this review aims to 
guide clinical decision-making and the direction of 
future research. 
METHODS
In line with best practice the full review protocol was developed 
a priori and registered with PROSPERO (http://www.crd.york.
ac.uk/PROSPERO/display_record.asp?ID=CRD42015025967).
Identification and selection of trials
Eight electronic databases were searched: MEDLINE (EBSCO), 
CINAHL (EBSCO), Cochrane Central Register of Controlled 
Trials (CENTRAL), REHABDATA, PEDro, NIHR Centre for 
Reviews and Dissemination, Scopus and clinicaltrials.gov. 
Search terms included “walking”,”electric* stimulat*”, equi-
novarus and Nervous system disease* ; The full search strategy 
is available from the lead author (SP). 
One reviewer (SP) assessed titles and abstracts against the 
inclusion criteria (Table I) and those deemed potentially relevant 
were considered by 2 independent reviewers (SP and PO). Any 
disagreements or ambiguity were resolved through discussion 
with a third reviewer (LK).
Data extraction and analysis
A pre-designed pro forma was used to extract data about the 
characteristics of the included trials, participants and interven-
tion details. Trial authors were contacted by SP if data were not 
readily available (Appendix I)
The Cochrane Risk of Bias Assessment Tool (33) was used 
independently by the 2 reviewers (SP and PO), with a third 
reviewer (LK) available if necessary. In order not to disadvan-
tage authors who did not respond to information requests, risk 
of bias was based only on published work. It is not possible to 
blind participants to which device they are given during the 
trial; therefore the performance bias criterion was removed. A 
post hoc sensitivity analysis was undertaken if 3 or more trials 
showed a high risk of bias, in which the meta-analysis was 
recalculated with those trials temporarily excluded to check 
whether they had influenced the results.
A range of outcome measures could evidence therapeutic ef-
fects; therefore any measure that captured walking behaviours 
when a device was not being worn following a period of use 
was extracted (Table I). In order to compare the therapeutic ef-
fects on the function of walking (question 1.), measures that sat 
within the Activity or Participation domains of the World Health 
Organization’s (WHO) International Classification of Functio-
ning, Disability and Health (ICF) model (34) were extracted. 
Activity monitoring was identified as the primary functional 
outcome measure (question 1.) because, unlike more controlled 
functional walking measures, it captures actual performance (35, 
36) as opposed to potential capacity (37). 
Although foot drop manifests itself in the same way for all 
CNS disorders, the possible impact of diagnosis on therapeutic 
effects (question 1i.) was explored by performing, where pos-
sible, sub-group analysis on individual CNS pathologies. This 
aimed to provide specific clinical guidance regarding which 
patients may benefit most from which device. 
The time course of therapeutic effects (question 1ii.) was 
explored by pooling data from trials that compared the devices 
at similar time-points. Some authors suggest that a period of 
use of 3 months is required to observe any therapeutic effects 
of either device (24). Sub-group meta-analysis was therefore 
sought at 12–13 weeks, as an approximation of 3 months. 
Table I. Inclusion criteria 
Design
Randomized controlled trials
Participants
Participants with foot drop caused by a CNS disorder
Intervention
Common peroneal nerve FES to address the specific impairment of foot 
drop, with or without other areas of stimulation
Trials where common peroneal stimulation is used during walking 
(overground or treadmill) as part of the intervention 
Trials studying the therapeutic effects of foot drop FES
Trials where foot drop FES and another intervention are used in 
combination, but foot drop FES is measured independently
Comparator
AFO (the term therapy was also included as might involve AFO)
Outcomes
Measures of walking
CNS: central nervous system; FES: functional electrical stimulation; AFO: 
ankle foot orthosis.
www.medicaljournals.se/jrm
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3Therapeutic effects of FES vs AFO for foot drop
In order to evidence potential mechanisms-of-
effect (question 2.), measures reflecting the Body 
Functions and Structures (BFS) domain are required 
(38). Given the assumption that FES, but not AFO, 
has a therapeutic effect on volitional muscle activity, 
electromyography (EMG) was chosen as a primary 
BFS measure of interest. As another key measure of 
gait (quality) is its kinematics (39), which may be 
influenced by muscle activations in complex ways, 
we chose to complement the EMG analysis with gait 
kinematics as a second primary BFS measure. Any 
other walking measure was deemed secondary and 
categorized as a functional measure of walking or 
BFS measures by SP, using appropriate literature (34, 
37, 40, 41). All primary and secondary end-point data 
were extracted. 
Where possible, mean differences (MD) with 95% 
confidence intervals (95% CIs) were used, where 
outcome measurements were comparable. If data 
collection methods varied then standardized mean 
differences (SMD) with 95% CIs were used. RevMan 
5.3® software was used.
Visual inspection of forest plot, χ2 test and I2 
statistic were used to examine heterogeneity. Low 
heterogeneity (< 50%) resulted in a fixed-effects and 
high (> 50%) in a random-effects model being used.
Where meta-analysis was not possible a narrative 
summary of the overall effects was presented. 
RESULTS
A total of 1,725 possible citations were found 
as a result of the searches. Following title, 
abstract and full-paper screening, a total of 8 papers 
met the inclusion criteria. Two of these papers (42, 
43) reported results from the same trial, and so were 
grouped and referred to by the first publication date 
(42), resulting in 7 RCTs, which included a total of 
464 participants (Fig. 1).
Characteristics of included trials
Six (14) of the 7 trials had a parallel-group RCT design. 
The remaining trial had a cross-over design with 2 AFO 
arms. Only 1 AFO arm was used, to avoid any issues 
associated with multiplicity (44); arm 2 (AFO-FES) 
was chosen due to its larger size and comparability to 
the FES arm (arm 1, FES-AFO) and final assessment 
data was deemed to be at 6 weeks, pre-cross-over (45), 
given the carry-over observed by the trial authors (46). 
Two trials collected data from multiple sites (14, 17), 
with the other 5 based at a single site (Table II). 
Participant details
Mean age ranged from 8 (47) to 61.58 (17) years, 
all participants had unilateral foot drop with an even 
distribution of right and left foot drop (182 right, 
50.3%, and 180 left, 49.7%). Where reported, more 
men than women were recruited (262 men, 62%, and 
159 women, 38%). 
Although Van der Linden et al. (47) included parti-
cipants with cerebral palsy (CP) (n = 14), the majority 
of participants (n = 450) had had a stroke (Table II). 
This allowed for sub-group analysis of this pathology 
(question 1i.). There were no trials that included any 
progressive CNS diagnoses. Medication was consi-
dered by 2 trials (Table II) (14, 17), with 1 screening 
based on no expected change in medication during the 
intervention period (14); compliance with medication 
was not reported by this trial.
Device details
Three trials (14, 17, 42) used “customized” AFOs that 
were either made or modified for the participant, by an 
appropriate clinician, on inclusion to the trial (Table 
II). Participants in 2 of the other trials used a variety 
of different types of AFO (29, 47) and participants in 
another trial used off-the-shelf orthoses (48), which 
was appropriate for the acute/sub-acute population 
they investigated (49). Four trials recruited participants 
who did not already use an AFO (12, 14, 42, 48), while 
Fig. 1. Flowchart of trial selection. RCT: randomized controlled trial; FES: functional 
electrical stimulation; AFO: ankle foot orthosis.
Records identified through database searching  
(n=1,725) 
MEDLINE 805  CINAHL 562         clinicaltrials.gov 17  
PEDro 90  CENTRAL 222         NIHR 3 
Naric 20   Scopus 6 
 
Additional records identified 
through other sources  
(n=40) 
Records after duplicates/obviously irrelevant removed  
(n=1,368) 
Records screened by titles and 
abstract  
(n=1,368) 
Records excluded  
(n =1,331) 
Reasons include: non-RCT design, not peroneal 
stimulation, not FES, participants were healthy, 
not exploring walking, non-human, technical or 
surgical exploration 
Full-text articles assessed for 
eligibility  
(n=37) 
Full-text articles excluded  
(n=29) 
 
Many had multiple reasons:- 
Design Not RCT: 6 
             Not FES/AFO comparison: 12 
Intervention Sensory stimulation only: 2 
       Not functional during walking: 1 
       Not peroneal nerve: 2 
Outcomes No walking measurements: 1 
     Not therapeutic effects: 4 
 
 
 
 
 
 
Papers  included  in  narrative  &   
meta-analysis  
(n=8, 2 combined so n=7) 
J Rehabil Med 49, 2017
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5Therapeutic effects of FES vs AFO for foot drop
the other trials recruited current AFO users (17, 29, 
47). None of the trials reported any of the mechanical 
properties of the AFO (Table II).
All trials recruited new users of FES. One trial used an 
implantable FES system (29), while the others opted for 
surface systems from 3 different manufacturers. Set-up 
parameters were reported by only 1 trial (47) (Table II).
Four trials allowed use within the home/community 
setting (14, 17, 29, 47), whilst the remaining 3 trials 
provided devices only under supervision (12, 42, 48) 
(Table II). 
Risk of bias
Table III shows the results of the Cochrane Risk of Bias 
Assessment. Kluding et al. (17) and Van der Linden 
et al. (47) were deemed to 
have no areas of high risk 
with Kottink et al. (29) 
showing the most high risk 
areas (three). Selection bias, 
as determined by the ability 
to generate an appropriately 
random sequence (33), was 
the area of risk least well 
addressed by the included 
trials (Table III). Based on 
these findings the trials were 
deemed to be at a moderate 
or lower risk of bias overall.
Outcome measures
All 7 trials used outcome 
measures that could be ca-
tegorized as functional and 
BFS (Table IV). Four of 
the trials utilized measures 
that we had deemed to be of 
primary interest (17, 29, 42, 
47). The most commonly 
used secondary measure 
was walking speed, which 
was primarily captured over 10 m. This was captured 
by 6 trials (12, 14, 17, 29, 42, 48) (n = 450).
Therapeutic effects – meta-analysis of gait speed
Salisbury et al. (48) reported data that reflected orthotic 
and therapeutic effects in combination. Despite repeated 
communication no specific therapeutic data was shared 
and so their results could not be included in meta-ana-
lyses. Meta-analysis of final-assessment walking speed 
data (Fig. 2a) of the other 6 trials (n = 437) showed that 
both interventions had equivalent positive therapeutic 
effects (MD = 0.02 [–0.03, 0.06]: I2 0%; p = 0.46). A 
sensitivity analysis was undertaken excluding the 3 
trials (12, 29, 42) that showed high risk of bias (Table 
III) with regards random sequence generation (selec-
Table III. Risk of bias
Author/reference
Random sequence 
generation (selection bias)
Allocation concealment 
(selection bias)
Blinding of outcome 
assessment 
(detection bias)
Incomplete outcome 
data (attrition bias)
Selective reporting 
(reporting bias)
Other 
bias
Everaert et al. (2013) (14) Unclear Unclear Unclear High Low Low
Kluding et al. (2013) (17) Low Low Unclear Low Low Unclear
Kottink et al. (2008) (29) High Unclear High Unclear High Unclear
Morone et al. (2012) (12) High High Unclear Low Low Low
Salisbury et al. (2013) (48) Unclear Low High Unclear Low Low
Sheffler et al. (2013) (42) High High Unclear Low Low Unclear
Van der Linden (2008) (47) Low Unclear Unclear Unclear Low Unclear
Fig. 2. (a) Final assessment of 10-m walking speed (m/s). (b) Sub-group analysis of 10-m walking speed 
for stroke (m/s). (c) Sub-group analysis of 10-m walking speed at 4–6 weeks (m/s).
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6 S. Prenton et al.
Table IV. Walking outcome measures and therapeutic effects
Author/
reference Walking outcome measures used & ICF level 
Outcome collection 
points 
Therapeutic effects reported at final outcome collection 
point: Significant p < 0.05 
Everaert et al. 
(2013) (14)
BFS:  
PCI over 4-min testb 
Functional:  
4-min walking test (speed)b 
10MWT  
Modified RMI
0, 3, 6 weeks Insignificant ↑ in all measures for both groups 
Kluding et al. 
(2013)c (17)
BFS: 
LE Fugl Meyer 
Functional:  
10MWT (self and fast)b 
TUG 
6-min walk test (distance)  
SIS mobility sub-scale 
Activity monitoring (Stepwatch®) for 7 consecutive 
days in weeks 6 and 24
0, 6, 12, 30 weeks LE Fugl Meyer: both groups showed ↑, AFO group was significant 
(insignificant between-group difference) 
Self and fast 10MWT: both groups showed significant ↑ 
(insignificant between-group difference) 
TUG: both groups showed ↑, FES group was significant 
(insignificant between-group difference) 
6-min walk test (distance): both groups showed significant 
improvement (insignificant between-group difference) 
SIS mobility sub-scale: both groups showed significant ↑ 
(insignificant between-group difference) 
Activity Monitoring: both groups showed improvement, 
significance was not reported
Kottink et al. 
(2008)c (29)
BFS:  
RMSMax TAb, PL, GS, SL with knee flexed and 
extended 
RMSswing TA 
Functional:  
10MWTb
0, 4, 8, 12, 26 weekse RMSMax TA: FES ↑ with knee flexed and extended. AFO did not 
have an effect. Significant between group difference with knee 
extended 
RMSMax PL and SL: Neither group showed an effect 
RMSMax GS: FES ↑ with knee flexed and extended, AFO 
caused an ↓ in flexion and did not have an effect in extension. 
Significant between group differences with knee flexed and 
extended 
RMSswing TA: remained constant for FES, significant ↓ for AFO  
10MWT: neither group showed an effect
Morone et al. 
(2012) (12)
BFS 
MRC muscle strength 
Ashworth scale 
Functional: 
10MWTb 
RMI 
FAC
0, approximately 1 
month
MRC muscle strength: both groups showed significant ↑ 
Ashworth scale: both groups showed ↑, but not significant 
10MWT: both groups showed significant ↑. FES group showed 
significantly more ↑ than AFO group. 
RMI: both groups showed significant ↑ 
FAC: both groups showed significant ↑. FES group showed 
significantly more ↑ than AFO group.
Salisbury et al. 
(2013) (48)
BFS: 
Cadence (10MWT) 
Functional: 
10MWT 
FAC 
SIS mobility sub-scale
0, 6, 12 weeks aCadence: both groups showed insignificant ↑ 
a10MWT: both groups showed insignificant ↑ 
aFAC: both groups showed insignificant ↑ 
aSIS mobility sub-scale: both groups showed insignificant ↑
Sheffler et al. 
(2013)c (42) 
BFS: 
LE Fugl Meyerb 
Spatiotemporal: cadence; stride length; double 
support time  
Proximal kinematic: peak hip flex in swingb; peak 
knee flex in swingb; peak hip ext in stance 
Distal kinematic: DF at IC; peak ankle DF in swing; 
peak ankle abd in swing; peak ankle ext rot in swing 
Kinetic: peak AP GRF; peak hip power in pre-swing; 
peak ankle power at push-off 
Functional: 
Walking speed 
mEFAP 
Activity Monitoring (ActivPAL®) for 3 consecutive 
days
0, 12, 24d, 36 weeksd LE Fugl Meyer: neither group showed ↑  
Spatiotemporal: Cadence and stride length: both groups 
showed significant ↑. Double support time: both group showed 
insignificant ↑ 
Kinematic: peak hip flex in swing, peak knee flex in swing, DF at 
IC, peak ankle abd in swing, peak ankle ext rot in swing showed 
insignificant changes. Peak ankle DF in swing: both groups 
showed significant ↓ at 12 and 24 weeks but not 36 weeks. Peak 
hip ext in stance: not reported. 
Kinetic: AP GRF, peak hip power in pre-swing and peak ankle 
power at push-off had both groups showing significant ↑ 
Walking speed: both groups showed significant ↑ 
mEFAP: both groups showed significant ↑ 
Activity Monitoring: no change in either group
Van der Linden 
et al. (2008)
c (47)
BFS: 
Kinematics: knee flex at IC; DF swing, foot floor 
angle 
Gilette Gait Index 
pROM: ankle DF with knee flex/ext 
Functional: 
Walking speed
0, 2, 10 weeks Knee flex at IC: both groups showed insignificant ↑ 
DF swing: FES showed insignificant ↑, AFO showed insignificant ↓ 
Gilette gait Index: both groups showed insignificant effects 
pROM: both groups showed insignificant effects 
Walking speed: FES showed insignificant ↑, AFO remained 
constant. 
aPublished results were therapeutic and combined-orthotic effects data; bidentified as primary outcome measure by authors; cused a primary outcome measure 
of interest, as identified by review authors; dpost 12 weeks use at 12 and 24 weeks, respectively; eRMSswing only collected at weeks 0 and 26. ↑ = increase; ↓ = 
decrease. 
abd: abduction; BFS: Body Functions & Structures; ICF: International Classification of Functioning Disability and Health; min: minute; LE: lower extremity; mEFAP: 
modified Emory Functional Ambulation Profile; TUG: Timed Up and Go; SIS: Stroke Impact Scale; 10MWT: 10-m walk test; PCI: Physiological Cost Index; RMI: 
Rivermead Mobility Index; FAC: Functional Ambulation Categories; MRC: Medical Research Council; FAC: Functional Ambulation categories; TA: tibialis anterior; 
GS: gastrocnemius; PL: peroneus longus; SL: soleus; RMSMax: root mean square during static maximum voluntary contraction; RMSswing: root mean square of 
activity during swing; DF: dorsiflexion; IC: initial contact; pROM: passive range of movement; AP: anterior-posterior; GRF: ground reaction force; flex: flexion; 
ext: extension; FES: functional electrical stimulation; AFO: ankle-foot orthosis.
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7Therapeutic effects of FES vs AFO for foot drop
with no change for the FES group, after 26 weeks use.
Two trials captured kinematic data (43, 47), but each 
collected different parameters (Table IV). Sheffler et al. 
(43) found a comparable lack of effect on most mea-
sures, but an equal decrease in peak DF during swing 
after the 12-week device use period (p = 0.002). This 
equal decrease in peak dorisflexion (DF) was again 
found 12 weeks after participants had finished using 
either device (p = 0.0001). When measured for the final 
time 24 weeks after participants had finished using 
their device the decrease in peak DF was no longer 
statistically significant, for either device (p = 0.058). 
By contrast, van der Linden et al. (47) found equal, but 
insignificant, improvement in all measures.
With regards to secondary measures, the lower ex-
tremity (LE) Fugl-Meyer test was a BFS measurement 
reported by 2 trials (17, 42). There were differences 
in their findings, with Kluding et al. (17) reporting 
improvement in both groups that, despite only the AFO 
group showing within-group statistically significant 
improvement (p < 0.05), was statistically comparable 
(p = 0.178). Sheffler et al. (42) found an equal between-
group lack of improvement (p = 0.321) (Table IV).
Across other measures used by single trials there 
was a mixture of therapeutic effects results reported 
across and/or within trials (Table IV).
DISCUSSION
This review shows, for the first time, that AFOs pro-
duce an equally positive therapeutic effect on walking 
speed to that of FES. These improvements are observed 
for stroke alone and are seen after 4–6 weeks of use. 
These findings are based on meta-analysis of RCT-
level evidence (33) and those RCTs were deemed to 
be of moderate (or less) risk of bias (33), meaning that 
there can be confidence in these findings. Equality 
of therapeutic effect on walking speed has not been 
demonstrated previously, as the focus of previous 
reviews (16, 32, 45, 50) and primary studies (51, 52) 
has been on the therapeutic effects of FES alone. What 
the RCT evidence does not answer is whether this im-
provement translates into activity within the person’s 
own environment. 
It is essential to gain a better understanding of 
whether therapeutic effects on walking speed translate 
into activity in a home setting, and the mechanisms 
by which therapeutic effects are achieved, in order 
to better inform clinical guidelines about which de-
vice to use for which patients. However, the included 
trials do not provide the measures needed to identify 
the mechanisms by which the devices achieve speed 
increases (question 2.). Narratively, there is a sugges-
tion bias). This showed no significant impact. Positive 
between-group comparability was also true for the stro-
ke-specific analysis (question 1i.) (n = 423) (MD = 0.02 
[–0.03, 0.07]: I2 0%; p = 0.54) (Fig. 2b).
Sub-group analysis of walking speed was not pos-
sible at 12–13 weeks (question 1ii.), as 1 of the 4 
trials (17, 29, 43, 48) that collected at this time-point, 
Kluding et al. (17), were contacted by the lead author 
but could not access their unpublished AFO data and, 
as previously stated, Salisbury’s (48) data was not in 
an accessible format. Five trials (12, 14, 17, 29, 48) 
collected walking speed data at 4–6 weeks (n = 116); 
meta-analysis of 3 of those trials (12, 14, 29) at this 
time-point showed a positive therapeutic effect with 
between-group comparability (MD = 0.03 [–0.06, 
0.12]: I2 0%; p = 0.49) (Fig. 2c). Kluding et al. (17) and 
Salisbury (48) could not be included in the analysis due 
the aforementioned lack of access to data.
Therapeutic effects – narrative summary for activity 
(steps), EMG, Kinematics and Fugl-Meyer
Two trials monitored activity levels by collecting 
the mean number of steps taken per day, the primary 
functional measure identified to evidence therapeutic 
effects on walking (question 1.) (17, 42). Kluding et al. 
(17) found equal improvement over the period of use 
(AFO group 1,891 steps/day at week 6 to 2,069 steps/
day at week 30; FES group 2,092 steps/day at week 6 
to 2,369 steps/day at week 30), whereas Sheffler et al. 
(42) found an equal lack of improvement (3,270 ± 2,947 
steps/day at baseline to 4,038 ± 2,848 steps/day at 24 
weeks post device use for AFO vs 3,223 ± 3,134 to 
3,738 ± 3,211 steps/day for FES). These could not be 
meta-analysed due to the lack of data spread reported 
and because activity was monitored during the inter-
vention period by Kluding et al. (17). Given that it was 
therefore not clear whether activity monitoring was 
performed with or without the devices being worn, the 
ability to interpret the outcome of activity monitoring 
is very limited.
With regards the mechanisms-of-effect (question 
2.), only 1 trial collected EMG data (29) (Table IV). 
This trial calculated the root mean square during 
static maximum voluntary contraction (RMSmax) of 
a filtered EMG signal and found that FES enhanced 
volitional activity of the tibialis anterior (TA), whereas 
AFO did not. This between-group difference was sig-
nificant when the knee was extended (p = 0.006), after 
26 weeks’ use. The same was true for the gastrocne-
mius (GS) when the knee was in flexion (p = 0.002) 
and extension (p = 0.035), after 26 weeks’ use. The 
RMS of TA during swing (RMSswing) was found to 
significantly decrease for the AFO group (p = 0.036) 
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8 S. Prenton et al.
tion that FES, but not AFOs, lead to improvement in 
voluntary muscle activity (29), although both produce 
equal effects on kinematic gait pattern (42, 47). 
One possible explanation is that remedying foot 
drop using either device allows increased time spent 
walking, thereby facilitating task-specific repetitive 
practice; which is widely accepted as leading to thera-
peutic improvement (21). However, from the activity 
monitoring results of the included RCTs it is unclear 
whether this occurs (17, 43), with non-RCT studies 
also finding variable results (53–55).
An alternative explanation for equivalent effects on 
walking speed may lie in how the increased walking 
speed is achieved; i.e. via restoration of motor function 
or compensation (56). True motor recovery is defined 
as the reversal of an impairment such that it results 
in the restitution of the functions governed by it (20). 
Compensation is a restoration of function achieved 
through adaptation or substitution of remaining motor 
elements (20). Being able to distinguish between reco-
very and compensation facilitates clinical decision-ma-
king and potentially increases intervention efficiency 
(21). Crucially, recognizing the distinction relies on an 
understanding of the mechanisms-of-effects.
The mechanisms-of-effects ascribed to FES are 
based on the fact that it is seen as an active orthosis, 
whereby volitional muscle activity is combined with 
lower motor neurone stimulation. This leads to a num-
ber of possible neuromuscular plastic mechanisms, 
including: repeated muscle contractions leading to 
increased oxidative capacity; increased number of 
micro-capillaries and change in fibre type at a mus-
cular level; convergence of orthodromic/antidromic 
impulses at the anterior horn leading to strengthe-
ning of synapses at a spinal level, as well as cortical 
changes (23–25). Structural cortical changes result 
from increased cortical excitability (26) are thought to 
strengthen the residual descending connections from 
motor-related areas of the cortex (24). In the case of 
therapeutic effects this culminates in increased volitio-
nal muscle activity of the weak dorsiflexors/evertors of 
the ankle, which is thought to positively influence other 
biomechanical features and therefore the restitution of 
associated functions.
In contrast, FES literature has asserted that AFOs, as 
passive devices, mask the abnormal muscle activation 
associated with foot drop impairment and so, whilst 
range of movement is maintained, neuromuscular plas-
ticity mechanisms result in a loss of volitional activity 
in those muscle groups over time (17, 29). This would 
mean that, in the absence of the AFO, other muscle 
groups will have to compensate for this deficit. 
In order to provide evidence for the hypothesis of 
differential changes in volitional muscle activation 
between FES and AFOs, both EMG and kinematic 
data of walking are needed. Only 1 trial included in 
this review provided EMG outcome measures (29), 
finding that FES use was associated with an increase in 
voluntary RMSmax for TA and GS, whereas AFO use 
was not. Similarly, with FES use voluntary activation 
of TA during swing was maintained relative to baseline, 
whereas following a period of AFO use TA activation 
declined during swing. This suggests that the ability 
to voluntarily activate TA and GS muscles may be 
maintained, or even improved by a period of FES use 
compared with AFO. Previous non-RCT studies and 
systematic reviews support this suggestion, as they have 
shown increased TA muscle activity, force and size with 
FES use (57–60) with the opposite occurring in AFO 
(4, 28, 30, 31). Further trials examining EMG following 
FES and AFO use are therefore needed if this potential 
mechanism-of-effect is to be more fully understood.
Despite the potential for differing effects on vo-
litional muscle activity, the RCT-evidence suggests 
that both devices have equal therapeutic effects on 
kinematic measures (43, 47); whether the effects are 
positive, negligible or negative is unclear. Non-RCT 
studies examining gait kinematics are limited with re-
gards to FES (39, 61) and AFO (62). Further kinematic 
comparative study is therefore required to identify 
whether improvement is compensatory or restorative 
and to correlate EMG data with functionally meaning-
ful improvements. 
These trials should consider how they both measure 
and define therapeutic effects. For example, in the 
included trials (17, 43) it was unclear whether acti-
vity (number of steps) was measured during walking 
while wearing the device, during walking when the 
device was not being worn, or a combination of both. 
Furthermore, the current definition of improvement 
in measured walking behaviours without the device 
being worn following a period of use (13) may not be 
clinically relevant.
In all the reviewed RCTs participants used the devi-
ces for a period of time, with measurement occurring 
immediately at the end of that period; with or without 
interim data collection points. This aligns with the 
definition of therapeutic effects and is consistent with 
its interpretation by non-RCT studies (63). However, 
these effects are clinically relevant only if the motor 
recovery  effect is sustained for a meaningful period of 
time for the individual. The intervention period for the 
participants within Sheffler et al.’s trial was 12 weeks, 
at which point they measured walking behaviours. In 
contrast to the other included trials, they also invited 
participants to additional data collection sessions 12 
and 24 weeks after they had finished using the devices 
(42). They found that the lack of effect on most mea-
sures reported after the intervention period was, unsur-
prisingly, sustained at these time-points. However, the 
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9Therapeutic effects of FES vs AFO for foot drop
equal decrease in peak DF during swing was sustained 
12 weeks post-use, but not 24 weeks post-use. Justifi-
cation of data collection time-points that align with an 
understanding of the mechanisms-of-effect and their 
clinical relevance are therefore needed. Only then will 
the time course of effects and the sustained therapeutic 
effects of the devices on measures, including kinema-
tics, be understood.
Strengths and limitations
This review adhered to the PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses) criteria (64, 65) and guidance from the 
Cochrane Collaboration (33). This, coupled with the 
specific questions and inclusion of RCTs only (66), 
enhances its validity. 
Our findings can only feasibly be generalized to a 
non-progressive CNS population, as data comes only 
from participants with stroke and CP. Further investiga-
tion into progressive CNS disorders is necessary, as the 
potential for therapeutic improvement has been shown 
to be limited with such conditions (54). Given that most 
individuals with CNS disorders will be on medication 
(e.g. anti-spasticity medication (67)), which could 
confound results, future trials should also consider 
how to control and report this variable.
Possible variability in the device design could 
limit the viability of the comparisons made by the 
primary trials and, by extension, this review. Lack of 
description of key aspects of either device means that 
the impact of pooling data from different FES set-up 
parameters and AFO mechanical properties cannot 
be explored (11, 25). However, given that both types 
of device were prescribed by qualified professionals, 
combining data from different trials reflects clinical 
practice and arguably improves the clinical validity 
of the findings. 
The risk of selection bias in the included trials was 
the greatest threat to the internal validity of our findings. 
This could mean that the estimates of effect are exagge-
rated (68, 69) but the inclusion of a sensitivity analysis 
excluding trials with high selection bias (12, 29) as a 
result of un-randomized sequence generation suggests 
there was no impact. Care should be taken to avoid 
this risk in future RCTs. There were a number of areas 
deemed to be unclear areas of risk across and within 
the RCTs; detailed reporting might have avoided this. 
Overall however, the RCTs were of at only moderate (or 
less) risk of bias, providing confidence in our findings.
Two trials could not be included in the meta-analysis 
because data was reported in such a way as to not al-
low analysis for the purpose of obtaining therapeutic 
effects. One of these trials would have provided ad-
ditional participants’ data for only 6 FES and 3 AFO, 
and so the effects are probably negligible (48). The 
absence of the full data-set from the 6- and 12-week 
data collection points from the other trial (17), n = 198, 
meant that no sub-group analysis of walking speed 
could be performed at the 12–13-week point. It may 
also have impacted the 4–6-week analysis, meaning 
that this aspect of therapeutic effects comparison 
(question 1ii.) could not be explored. Future RCTs 
should report the raw results for all planned primary 
and secondary end-points and separate data relating to 
different effects (70).
Conclusion
This meta-analysis shows, for the first time, that FES 
and AFO are statistically proven to have the same 
therapeutic effect on walking speed in CNS foot drop. 
This effect has also specifically been shown to occur 
for foot drop caused by stroke and is observed after 
4–6 weeks’ use. Nevertheless, whether this increase in 
walking speed translates into increased activity in the 
person’s own environment, and how this improvement 
is achieved, remain unclear. Future research should the-
refore focus on the measures suggested in this review in 
order to address this gap in the evidence base and, with 
regards activity monitoring, address when the measures 
are captured. In addition to measurement, future trials 
must also report specific device details, capture sustai-
ned therapeutic effects and should involve a variety of 
CNS diagnoses with justified primary and secondary 
end-points. Only then can clinical decision-making 
be significantly advanced and supported by a robust 
evidence base.
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